Hepatobiliary Diagnostic Procedures with MCC DRG Reimbursement

DRG 420 pertains to hepatobiliary diagnostic procedures performed in the inpatient setting when a Major Complication or Comorbidity is present; it encompasses advanced biliary and liver diagnostic interventions alongside significant patient acuity. This Diagnosis-Related Group is important for inpatient reimbursement because the Major Complication or Comorbidity status increases payment weighting to reflect higher resource consumption.

DRG 420 Overview

DRG 420 covers inpatient cases involving hepatobiliary diagnostic procedures with a Major Complication or Comorbidity present, typically including advanced imaging, endoscopic retrograde cholangiopancreatography, or intraoperative diagnostic interventions for liver, biliary, or pancreatic disease. This Diagnosis-Related Group reflects higher resource use driven by the complexity of diagnostic workup and the presence of serious comorbid conditions. It matters for Medicare payment because the presence of a Major Complication or Comorbidity increases relative payment to account for greater intensity of care and longer hospital resources. Accurate clinical documentation and coding of the procedures and the Major Complication or Comorbidity are central to proper Classification in this Diagnosis-Related Group.

DRG 420 Overview

Acute diagnostic accuracy and safety studies of advanced hepatobiliary imaging and endoscopic procedures: trials focusing on optimizing timing, modality combinations (e.g., high-resolution MRCP, contrast-enhanced ultrasound, and endoscopic retrograde cholangiopancreatography equivalents), and procedural safety in hospitalized patients presenting with suspected obstructive jaundice, cholangitis, or postoperative biliary complications. The patient population includes acutely ill inpatients with suspected biliary obstruction or infection and often multiple comorbidities; studies assess sensitivity/specificity, complication rates, and impact on time-to-diagnosis. These studies are relevant to providers and payers because more accurate, timely diagnostics can reduce length of stay, avoid unnecessary surgeries, and allocate high-cost procedural resources more effectively.
Comparative effectiveness trials of diagnostic-driven management pathways in complex hepatobiliary disease: randomized or pragmatic studies comparing strategies such as early endoscopic/interventional biliary decompression versus conservative imaging-first approaches, or surgical referral thresholds based on biomarker and imaging algorithms in patients with suspected malignant or benign biliary strictures. The enrolled population includes hospitalized adults with intermediate-to-high pretest probability for biliary malignancy or severe benign obstruction who require decisions about invasive diagnostic procedures with major cost and morbidity implications. Results inform which pathways achieve better clinical outcomes, lower complication rates, and cost-effectiveness — data that help clinicians choose appropriate care plans and help payers design coverage and utilization policies.
Post-procedural outcomes and readmission reduction studies targeting high-risk hepatobiliary patients: cohort and interventional studies that evaluate predictors of 30-day readmission, complications, and functional recovery after inpatient hepatobiliary diagnostic procedures, including care-transition interventions, standardized discharge protocols, and outpatient follow-up strategies. These studies focus on medically complex patients (advanced age, liver disease, sepsis risk) who undergo diagnostic procedures during an admission and are at risk for early complications or repeat hospital use. Findings are important to providers for improving peri-procedural management and to payers for reducing avoidable readmissions and downstream costs while maintaining quality metrics.

Acute diagnostic accuracy and safety studies of advanced hepatobiliary imaging and endoscopic procedures: trials focusing on optimizing timing, modality combinations (e.g., high-resolution MRCP, contrast-enhanced ultrasound, and endoscopic retrograde cholangiopancreatography equivalents), and procedural safety in hospitalized patients presenting with suspected obstructive jaundice, cholangitis, or postoperative biliary complications. The patient population includes acutely ill inpatients with suspected biliary obstruction or infection and often multiple comorbidities; studies assess sensitivity/specificity, complication rates, and impact on time-to-diagnosis. These studies are relevant to providers and payers because more accurate, timely diagnostics can reduce length of stay, avoid unnecessary surgeries, and allocate high-cost procedural resources more effectively.
Comparative effectiveness trials of diagnostic-driven management pathways in complex hepatobiliary disease: randomized or pragmatic studies comparing strategies such as early endoscopic/interventional biliary decompression versus conservative imaging-first approaches, or surgical referral thresholds based on biomarker and imaging algorithms in patients with suspected malignant or benign biliary strictures. The enrolled population includes hospitalized adults with intermediate-to-high pretest probability for biliary malignancy or severe benign obstruction who require decisions about invasive diagnostic procedures with major cost and morbidity implications. Results inform which pathways achieve better clinical outcomes, lower complication rates, and cost-effectiveness — data that help clinicians choose appropriate care plans and help payers design coverage and utilization policies.
Post-procedural outcomes and readmission reduction studies targeting high-risk hepatobiliary patients: cohort and interventional studies that evaluate predictors of 30-day readmission, complications, and functional recovery after inpatient hepatobiliary diagnostic procedures, including care-transition interventions, standardized discharge protocols, and outpatient follow-up strategies. These studies focus on medically complex patients (advanced age, liver disease, sepsis risk) who undergo diagnostic procedures during an admission and are at risk for early complications or repeat hospital use. Findings are important to providers for improving peri-procedural management and to payers for reducing avoidable readmissions and downstream costs while maintaining quality metrics.

OpenPayer

Hepatobiliary Diagnostic Procedures with MCC: Inpatient Reimbursement Overview

Sign up for drg 420 policy alerts

DRG 420 Overview

OpenPayer

Hepatobiliary Diagnostic Procedures with MCC: Inpatient Reimbursement Overview

Sign up for drg 420 policy alerts

DRG 420 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References